Allspring中小型核心主动型ETF ASCE 深 沪
等待开盘 02-06 09:30:00 美东时间
27.86
-0.240
-0.85%
华盛通- 最 高28.115
- 今 开28.06
- 成交量 2.54万股
- 最 低 27.77
- 昨 收 28.10
- 总市值 4329.44万
- 52周最高 28.95
- 市盈率 静 --
- 换手率 1.63%
- 52周最低 24.0619
- 委 比 0.00%
- 总股本 155.40万
- 历史最高 28.95
- 量 比 1.34
- 振 幅 1.23%
- 历史最低 24.0619
- 每 手 1
- 风险率 1.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Liquidia Unveils New Clinical Data on Inhaled Treprostinil Therapies at PVRI 2026 Congress
Liquidia Unveils New Clinical Data on Inhaled Treprostinil Therapies at PVRI 2026 Congress Liquidia Corporation announced that it will present new clinical data across its portfolio at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress, taking place January 28 through February 1,
01-28 01:27
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results Jan 21 (Reuters) - Gilead Sciences Inc GILD.O : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE
01-22 06:18
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC Gilead Sciences Inc. announced the publication of full results from the Phase 3 ASCENT-04/KEYNOTE-D19 clinical trial in The New England Journal of Medicine. The study evaluated the efficacy and sa
01-22 06:00
Allspring Launches 3 Active ETFs, Including 1 For Tax-Free Income
Allspring's three new actively managed ETFs offer exposure to quality stocks and ultra-short municipal bonds with tax-free income potential.
2025-07-09 03:39
ALLSPRING LAUNCHES ACTIVE EQUITY, MUNI ETFs
ALRG, ASCE, and AUSM join growing suite of ETFs, all based on proven strategies CHARLOTTE, N.C., July 8, 2025 /PRNewswire/ -- Allspring Global Investments™, a global asset management firm wi...
2025-07-08 20:31
BRIEF-Ascentage Pharma Announces Pricing Of U.S. Initial Public Offering
Jan 23 (Reuters) - Ascentage Pharma Group International 6855.HK: ASCENTAGE PHARMA ANNOUNCES PRICING OF U.S. INITIAL PUBLIC OFFERING ASCENTAGE PHARMA GROUP INTERNATIONAL: PRICING OF ITS U.S. INITIAL PU...
2025-01-24 07:44
BRIEF-Ascend Wellness Holdings Closes $15 Million Private Placement Of Senior Secured Notes
Jan 14 (Reuters) - Ascend Wellness Holdings Inc AAWH.PK: ASCEND WELLNESS HOLDINGS CLOSES $15 MILLION PRIVATE PLACEMENT OF SENIOR SECURED NOTES Source text: ID:nCNWPCZfja Further company coverage: AAWH...
2025-01-14 21:15
BRIEF-Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency
Jan 6 (Reuters) - Arcturus Therapeutics Holdings Inc ARCT.O: ARCTURUS THERAPEUTICS ANNOUNCES INITIATION OF DOSING IN PHASE 2 MULTIPLE ASCENDING DOSE STUDIES FOR CYSTIC FIBROSIS (CF) AND ORNITHINE TRAN...
2025-01-07 05:14
